In Latin American and the Carribean region, so far, nine countries have begun inoculating their populations against COVID-19 and all of them are providing free vaccination to all citizens
Pfizer Inc. is accused of aiming for more profits by not ensuring the delivery of the promised quantity of COVID-19 vaccines after it was found that medics could draw six doses of vaccine per bottle instead of the expected five doses
Bolivia hopes to vaccinate up to 20% of its population in the first quarter of this year. The health ministry has endorsed Russia’s Sputnik V and China’s CoronaVac vaccines against COVID-19
On December 24, the South American nation received the first 300,000 doses out of a total order of over 10 million doses of the Russian Sputnik V vaccine. In the first round it has prioritized the health workers for the administration of the vaccine.
India’s mass vaccination plans may fail if it does not hold open discussions on its plans with health professionals and the people
As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard
Both Russia’s Sputnik V and the UK’s Pfizer-BioNTech-produced vaccines are reported to be more than 95% effective in their final trials
The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials
If we plan to vaccinate the entire Indian people, the states need to be involved in a big way, however, the Modi government has so far centralized all aspects of the management of the epidemic, treating it only as an administrative problem.
Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss the challenges of taking a vaccine to the people in countries like India. They also look at the various vaccine candidates in contention
According to a recent study by Oxfam International, wealthy nations, which account for nearly 13% of the global population, have cornered a lion’s share of supply deals for vaccine candidates in phase-3 of the clinical trials